Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with...

Full description

Saved in:
Bibliographic Details
Published inThe oncologist (Dayton, Ohio) Vol. 16; no. 4; pp. 388 - 403
Main Authors Ludwig, Heinz, Beksac, Meral, Bladé, Joan, Cavenagh, Jamie, Cavo, Michele, Delforge, Michel, Dimopoulos, Meletios, Drach, Johannes, Einsele, Hermann, Facon, Thierry, Goldschmidt, Hartmut, Harousseau, Jean‐Luc, Hess, Urs, Kropff, Martin, Leal da Costa, Fernando, Louw, Vernon, Magen‐Nativ, Hila, Mendeleeva, Larisa, Nahi, Hareth, Plesner, Torben, San‐Miguel, Jesús, Sonneveld, Pieter, Udvardy, Miklos, Sondergeld, Pia, Palumbo, Antonio
Format Journal Article
LanguageEnglish
Published Durham, NC, USA AlphaMed Press 01.01.2011
Subjects
Academia-Pharma Intersect
Age Factors
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Boronic Acids - therapeutic use
Bortezomib
Comorbidity
Congresses as Topic
Disease-Free Survival
Europe
Evidence-Based Practice
Humans
Medicin och hälsovetenskap
Multiple Myeloma - drug therapy
Multiple Myeloma - therapy
Pyrazines - therapeutic use
Stem Cell Transplantation
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Treatment Outcome
Europe
Online AccessGet full text

Cover

More Information
Summary:The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence‐based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. 摘要 新型药物沙利度胺、硼替佐米以及来那度胺的使用大大改变了多发性骨髓瘤的治疗模式，更重要的是，患者转归得以明显改善。对上述药物在不同治疗背景下的疗效评估有助于循证决策的建立，以形成最佳的治疗模式。本综述是对以前欧洲各国治疗实践的更新，回顾了截至2010年底已发表或大会提交的最新数据，并评价对治疗模式的影响。 This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.
Bibliography:Research funding/contracted research
Celgene
Pia Sondergeld
Johannes Drach
Vernon Louw
Ortho Biotech, Celgene
Hila Magen‐Nativ
Larisa Mendeleeva
Janssen, Celgene, Onyx
Janssen, Celgene, Amgen
Celgene, Janssen, Novartis, Onyx, Bristol‐Myers Squibb
Hareth Nahi
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.
MSD, Janssen, Celgene
Millennium, Celgene, Janssen, Novartis
Michel Delforge
Urs Hess
Jesús San‐Miguel
Consultant/advisory role
Torben Plesner
Pieter Sonneveld
Jean‐Luc Harousseau
Celgene, Janssen
This is a position paper of the European Myeloma Network (EMN).
Janssen‐Cilag, Mundipharma
Celgene, Janssen‐Cilag, Mundipharma
Michele Cavo
Joan Bladé
Celgene, Janssen‐Cilag
Meletios Dimopoulos
Disclosures: Heinz Ludwig
Jamie Cavenagh
Thierry Facon
Celgene, Janssen‐Cilag, Merck, Amgen.
Celgene, Ortho Biotech, Novartis
Janssen
Hartmut Goldschmidt
Celgene, Ortho Biotech, Mundipharma
Miklos Udvardy
Martin Kropff
Hermann Einsele
Fernando Leal da Costa
Celgene, Janssen, Mundipharma
Antonio Palumbo
Celgene, Janssen‐Cilag, Novartis
Janssen, Celgene
Meral Beksac
None
Honoraria
Disclosures: Heinz Ludwig: Honoraria: Celgene, Ortho Biotech, Mundipharma; Research funding/contracted research: Celgene, Ortho Biotech, Mundipharma; Meral Beksac: Consultant/advisory role: Celgene; Honoraria: Celgene, Janssen-Cilag, Novartis; Joan Bladé: None; Jamie Cavenagh: None; Michele Cavo: None; Michel Delforge: Honoraria: Celgene, Janssen-Cilag; Research funding/contracted research: Celgene, Janssen-Cilag; Meletios Dimopoulos: Honoraria: Celgene, Ortho Biotech, Novartis; Johannes Drach: Consultant/advisory role: Janssen-Cilag, Mundipharma; Honoraria: Celgene, Janssen-Cilag, Mundipharma; Hermann Einsele: Consultant/advisory role: Celgene, Janssen-Cilag, Novartis; Honoraria: Celgene, Janssen-Cilag, Novartis; Research funding/contracted research: Celgene, Janssen-Cilag, Novartis; Thierry Facon: Consultant/advisory role: Janssen, Celgene; Hartmut Goldschmidt: Consultant/advisory role: Celgene, Janssen, Mundipharma; Honoraria: Celgene, Janssen, Mundipharma; Research funding/contracted research: Celgene; Jean-Luc Harousseau: Consultant/advisory role: Celgene, Janssen, Novartis, Onyx, Bristol-Myers Squibb; Honoraria: Celgene, Janssen; Urs Hess: Consultant/advisory role: Janssen, Celgene; Martin Kropff: Honoraria: Ortho Biotech, Celgene; Fernando Leal da Costa: Consultant/advisory role: MSD, Janssen, Celgene; Honoraria: Janssen, Celgene, Amgen; Vernon Louw: Research funding/contracted research: Janssen; Hila Magen-Nativ: None; Larisa Mendeleeva: None; Hareth Nahi: None; Torben Plesner: None; Jesús San-Miguel: Consultant/advisory role: Millennium, Celgene, Janssen, Novartis; Honoraria: Millennium, Celgene, Janssen, Novartis; Pieter Sonneveld: Honoraria: Janssen, Celgene, Onyx; Research funding/contracted research: Janssen, Celgene, Onyx; Miklos Udvardy: None; Pia Sondergeld: None; Antonio Palumbo: Consultant/advisory role: Celgene, Janssen-Cilag; Honoraria: Celgene, Janssen-Cilag, Merck, Amgen.
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1634/theoncologist.2010-0386